<div id="readability-page-1"><p>Qiagen N.V. (NYSE:QGEN - Free Report)'s stock is going to reverse split before the market opens on Thursday, January 8th. The 19-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, January 7th.</p><h2>Qiagen Price Performance</h2><ul><li>Strategic Buy Lights Up This Biotech Stock: Time to Invest?</li></ul><p>QGEN stock opened at $45.30 on Friday. The company has a market capitalization of $10.07 billion, a PE ratio of 24.62, a P/E/G ratio of 2.32 and a beta of 0.68. The company has a quick ratio of 2.30, a current ratio of 2.60 and a debt-to-equity ratio of 0.45. The stock's 50 day moving average is $46.10 and its two-hundred day moving average is $47.10. Qiagen has a 52-week low of $37.63 and a 52-week high of $51.88. </p><p>Qiagen (NYSE:QGEN - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.58 by $0.03. The company had revenue of $532.58 million during the quarter, compared to analysts' expectations of $525.68 million. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.The business's revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.57 EPS.  Analysts predict that  Qiagen will post 2.26 earnings per share for the current fiscal year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several equities analysts have recently commented on QGEN shares. Weiss Ratings  reaffirmed a &#34;hold (c)&#34; rating on shares of Qiagen in a research report on Monday. Citigroup downgraded Qiagen from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and reduced their target price for the stock from $55.00 to $50.00 in a report on Thursday, December 11th. Wall Street Zen upgraded Qiagen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Sunday, December 21st. Finally, Barclays  reissued an &#34;overweight&#34; rating and set a $55.00 price target (up from $53.00) on shares of Qiagen in a research report on Monday, December 15th. Two analysts have rated the stock with a Buy rating and eight have issued  a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of &#34;Hold&#34; and an average target price of $49.61.</p><p><b>View Our Latest Analysis on Qiagen</b></p><h2>Hedge Funds Weigh In On Qiagen</h2><p>Several hedge funds and other institutional investors have recently modified their holdings of QGEN. Danske Bank A S bought a new position in shares of  Qiagen during the third quarter worth about $36,000.  Smartleaf Asset Management LLC boosted its stake in  Qiagen by 1,383.3% during the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company's stock valued at $39,000 after purchasing an additional 830 shares during the period.  MAI Capital Management grew its position in  Qiagen by 998.9% in the 2nd quarter. MAI Capital Management now owns 978 shares of the company's stock worth $47,000 after purchasing an additional 889 shares during the last quarter.  Farther Finance Advisors LLC increased its stake in shares of  Qiagen by 400.5% in the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company's stock valued at $51,000 after purchasing an additional 849 shares during the period.  Finally, Allworth Financial LP increased its stake in shares of  Qiagen by 260.1% in the second quarter. Allworth Financial LP now owns 1,102 shares of the company's stock valued at $53,000 after purchasing an additional 796 shares during the period. Institutional investors and hedge funds own  70.00% of the company's stock. </p><h2>Qiagen Company Profile</h2> (Get Free Report)<p>Qiagen NV <span>NYSE: QGEN<span></span></span> is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.  </p><p>The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Qiagen</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Do you know what Amazon is planning for January 1?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Qiagen Right Now?</h2><p>Before you consider Qiagen, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Qiagen wasn't on the list.</p><p>While Qiagen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

QGEN

<p>Qiagen N.V. (NYSE:QGEN) will undergo a 19-20 reverse stock split on January 8th. Shareholders' holdings will be adjusted after the market closes on January 7th. The company recently reported earnings that exceeded expectations, with a revenue increase of 6.2% year-over-year. Analysts have mixed ratings on the stock, with a consensus rating of 'Hold' and an average target price of $49.61. Institutional investors own 70% of Qiagen's stock.</p>

Qiagen (NYSE:QGEN) Shares Set to Reverse Split on Thursday, January 8th